Review Highlights Evolving Therapeutic Strategies for Chronic Kidney Disease in Diabetes Mellitus

Diabetes Mellitus (DM) is a rapidly escalating global health crisis, with nearly half of affected patients developing Chronic Kidney Disease (CKD), often progressing to End-Stage Kidney Disease (ESKD). This imposes significant burdens on patients and healthcare systems. Historically, standard of care for CKD in Type 2 Diabetes (T2D) focused on renin-angiotensin-aldosterone system (RAAS) inhibition, blood pressure optimization, and glycemic control. However, RAAS monotherapy has proven insufficient to halt CKD progression in many patients, necessitating new therapeutic approaches.

This review article synthesizes the evolution of therapeutic strategies for diabetic kidney disease (DKD), particularly since 2019. It examines the shift from traditional management, centered on RAAS inhibition, to the integration of novel drug classes. The authors discuss the clinical approval and integration of these new agents, highlighting their proven kidney and cardiovascular benefits. The paper aims to provide an updated perspective on optimizing treatment outcomes for patients with CKD and DM by focusing on organ-protective therapies beyond glycemic control.

The review emphasizes that the therapeutic landscape for diabetic kidney disease (DKD) has expanded rapidly since 2019, moving beyond the previous standard of care which relied on renin-angiotensin-aldosterone system (RAAS) inhibition, blood pressure optimization, and intensive glycemic control. > The emergence of multiple new drug classes has significantly transformed DKD management, demonstrating proven kidney and cardiovascular benefits that were not fully achieved with RAAS monotherapy alone. These novel agents address the persistent challenge of CKD progression in patients with Type 2 Diabetes (T2D), where nearly 20% progress to very high CKD risk within 5 years. The review underscores the critical need for therapies that offer organ protection, given that DM is the primary driver of ESKD, accounting for nearly half of all new dialysis cases in Canada.